Biliary reflux

Global Aluminum Hydroxide Market Report 2022: A $2.46 Billion Market by 2027 - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Natural Resources, Other Manufacturing, Manufacturing, Mining, Minerals, COVID-19, Heartburn, Electronics, Nature, Prevalence, Biliary reflux, Conditional sentence, R, Plastic, Zeolite, Transport, Elastomer, Aluminium, Adhesive, Research, Polymer, Aluminium hydroxide, Investment, Magnesium hydroxide, Potash, Growth

The "Aluminum Hydroxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aluminum Hydroxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global aluminum hydroxide market reached a value of US$ 1.78 billion in 2021.
  • How has the global aluminum hydroxide market performed so far and how will it perform in the coming years?
  • What is the structure of the global aluminum hydroxide market and who are the key players?

Implantica Presents RefluxStop's Health Economic Impact at ISPOR Europe 2022

Retrieved on: 
Thursday, November 10, 2022
Quality of life, GERD, Biliary reflux, International Society, Medtech, Pharmacoeconomics, Anatomy, Technology, University of York, AG, Magnetism, PPI, Standard of care, Conference, Patient, CEO, Payment, Insurance, Medical device

), a MedTech company at the forefront of bringing advanced technology into the body, attended the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference Europe 2022 that was held 6-9 November, in Vienna, Austria and Virtual #ISPOREurope.

Key Points: 
  • ), a MedTech company at the forefront of bringing advanced technology into the body, attended the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference Europe 2022 that was held 6-9 November, in Vienna, Austria and Virtual #ISPOREurope.
  • ISPOR isthe leading European conference for Health Economics and Outcomes Research (HEOR) held for discussion and dissemination of the latest trends in healthcare.
  • Implantica presented on the health economic impact of RefluxStopTMa new surgical solution that corrects the anatomy of the body to resolve the cause of acid reflux.
  • "Implantica presented our very positive economic impact results: RefluxStop provides higher quality of life than the competing treatments by providing better symptom control with fewer side effects.

Implantica presents the third quarter 2022 on November 15 at 15:00 CET

Retrieved on: 
Wednesday, November 9, 2022
Nasdaq, Certification, Skin, Clinical trial, Patent, CET, EHealth, Biliary reflux, Medical device

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

Key Points: 
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
  • The company's Certified Adviser is FNCA Sweden AB, [email protected]
    The information was sent for publication, through the agency of the contact person set out above, on November 9, 2022 at 3:30 p.m. CET.
  • Implantica is a medtech group dedicated to bringing advanced technology into the body.
  • Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).

Implantica presents a robust health economic analysis of RefluxStop™ conducted by University of York, UK

Retrieved on: 
Monday, August 22, 2022
Patent, CEST, Clinical trial, Biliary reflux, Nasdaq, Skin, Certification, EHealth, Medical device

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

Key Points: 
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
  • Implantica is a medtech group dedicated to bringing advanced technology into the body.
  • Implantica's lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.
  • Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).

Implantica presents the second quarter 2022 on August 23 at 15:00 CEST

Retrieved on: 
Wednesday, August 17, 2022
Clinical trial, Biliary reflux, EHealth, Certification, Patent, Skin, Nasdaq, CEST, Medical device

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

Key Points: 
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
  • The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]
    The information was sent for publication, through the agency of the contact person set out above, on August 17, 2022 at 1:00 p.m. CEST.
  • Implantica is a medtech group dedicated to bringing advanced technology into the body.
  • Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).

Gastrointestinal Drug Market Report 2022: Trends, Forecast and Competitive Analysis, 2016-2027 by Drug Class, Route of Administration, Application, Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022
Health, Pharmaceutical, Investment, Competitive analysis, GERD, Acid, Biliary reflux, Prescription Drug Marketing Act, Irritable bowel syndrome, Gastroesophageal reflux disease, Inflammatory bowel disease, Government, CAGR, R, Growth, Dietary supplement, Fine chemical

The "Gastrointestinal Drug Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Drug Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The global gastrointestinal drug market is expected to grow with a CAGR of 4%-6% from 2022 to 2027.
  • The future of the gastrointestinal drug market looks promising with opportunities in the cure of gastro-esophageal reflux disease, inflammatory bowel disease, and irritable bowel syndrome disorders/applications.
  • The study includes a forecast for the global gastrointestinal drug market by drug class, route of administration, application, distribution channel, and region.

Implantica engages Pareto Securities as liquidity provider

Retrieved on: 
Monday, July 18, 2022
CEST, Patent, Skin, EHealth, Biliary reflux, Nasdaq, Clinical trial, Certification, Medical device

VADUZ, Liechtenstein, July 18, 2022 /PRNewswire/ -- Implantica has entered into an agreement with Pareto Securities whereby Pareto Securities will act as liquidity provider for the Implantica share. The assignment takes place within the framework of Nasdaq First North Growth Market's liquidity provision rules and means that the liquidity provider quotes a buy and sell volume corresponding to at least SEK 20,000, with a maximum spread of 4% between the bid and ask price. The purpose is to promote the share's liquidity, and the assignment commences on Monday, July 18, 2022.

Key Points: 
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
  • The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]
    The information was sent for publication, through the agency of the contact person set out above, on July 18, 2022, at 10:20 a.m. CEST.
  • Implantica is a medtech group dedicated to bringing advanced technology into the body.
  • Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).

Global $10.84 Bn Antacids Markets, Analysis, & Forecasts 2016-2021, 2021-2026F, 2031F by Drug Class, Distribution Channel, Formulation Type - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022
Medical Supplies, Retail, Health, Other Retail, Pharmaceutical, Food, Beverage, Proton, Title 21 of the Code of Federal Regulations, Constipation, American College, Acid, Boehringer Ingelheim, Biliary reflux, AstraZeneca, OTC, Wickham Laboratories Ltd, Code, Stomach, Bayer, Aluminium, FDA, H2, Takeda Pharmaceutical Company, Efficiency, Hydrogen potassium ATPase, CFR, American College of Gastroenterology, Herbal, Antacid, GlaxoSmithKline, Heartburn, Enzyme inhibitor, Technology, Milk-alkali syndrome, Hypophosphatemia, Mouth, Prevalence, Growth, Osteomalacia, Abbott Laboratories, Absorption, Gastroesophageal reflux disease, Pfizer, Pharmacy, Sleep, Maalox, Mylanta

The "Antacids Global Market Report 2022, By Drug Class, Distribution Channel, Formulation Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antacids Global Market Report 2022, By Drug Class, Distribution Channel, Formulation Type" report has been added to ResearchAndMarkets.com's offering.
  • The antacids market consists of sales of antacids which are used to neutralize stomach acid, and treat acid reflux, heartburn and indigestion.
  • The main classes of antacids are proton pump inhibitors, h2 antagonist, acid neutralizers and pro-motility agents.
  • Proton-pump inhibitors are a type of drug that reduces stomach acid production significantly and for a long time.

Implantica presents the first quarter 2022 on May 11 at 15:00 CEST

Retrieved on: 
Thursday, May 5, 2022
CEST, Biliary reflux, Patent, Certification, Skin, EHealth, Nasdaq, Clinical trial, Medical device

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

Key Points: 
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
  • The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]
    The information was sent for publication, through the agency of the contact person set out above, on May 5, 2022 at 1:00 p.m. CEST.
  • Implantica is a medtech group dedicated to bringing advanced technology into the body.
  • Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).

Implantica presents the fourth quarter 2021 on February 18 at 15:00 CET

Retrieved on: 
Monday, February 14, 2022
Certification, Patent, CET, Skin, Clinical trial, Biliary reflux, Nasdaq, EHealth, Weapon, Medical device

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

Key Points: 
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
  • The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]
    The information was sent for publication, through the agency of the contact person set out above, on February 14, 2022 at 08:30 a.m. CET.
  • Implantica is a medtech group dedicated to bringing advanced technology into the body.
  • Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB).